- Home
- MOLN vs WNEB Comparison
MOLN vs WNEB Comparison
Compare MOLN & WNEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- WNEB
- Stock Information
- Founded
- MOLN 2004
- WNEB 1853
- Country
- MOLN Switzerland
- WNEB United States
- Employees
- MOLN N/A
- WNEB N/A
- Industry
- MOLN
- WNEB Savings Institutions
- Sector
- MOLN
- WNEB Finance
- Exchange
- MOLN Nasdaq
- WNEB Nasdaq
- Market Cap
- MOLN 195.4M
- WNEB 191.1M
- IPO Year
- MOLN 2021
- WNEB N/A
- Fundamental
- Price
- MOLN $5.33
- WNEB $8.92
- Analyst Decision
- MOLN
- WNEB Hold
- Analyst Count
- MOLN 0
- WNEB 3
- Target Price
- MOLN N/A
- WNEB $8.50
- AVG Volume (30 Days)
- MOLN 6.1K
- WNEB 42.4K
- Earning Date
- MOLN 03-13-2025
- WNEB 02-04-2025
- Dividend Yield
- MOLN N/A
- WNEB 3.14%
- EPS Growth
- MOLN N/A
- WNEB N/A
- EPS
- MOLN N/A
- WNEB 0.52
- Revenue
- MOLN $7,105,397.00
- WNEB $72,500,000.00
- Revenue This Year
- MOLN N/A
- WNEB N/A
- Revenue Next Year
- MOLN $29.41
- WNEB $6.24
- P/E Ratio
- MOLN N/A
- WNEB $17.27
- Revenue Growth
- MOLN N/A
- WNEB N/A
- 52 Week Low
- MOLN $3.32
- WNEB $6.00
- 52 Week High
- MOLN $12.70
- WNEB $10.08
- Technical
- Relative Strength Index (RSI)
- MOLN 49.14
- WNEB 45.35
- Support Level
- MOLN $5.25
- WNEB $8.51
- Resistance Level
- MOLN $5.33
- WNEB $9.20
- Average True Range (ATR)
- MOLN 0.20
- WNEB 0.17
- MACD
- MOLN 0.02
- WNEB 0.01
- Stochastic Oscillator
- MOLN 44.23
- WNEB 57.75
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the Company's revenues, profits, and assets are derived by the Bank from banking products and services.